Cargando…

SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation

OBJECTIVE: This study aimed to verify the survival superiority of the combination of intraperitoneal perfusion and systemic chemotherapy over standard systemic chemotherapy. METHODS: A total of 78 advanced gastric cancer patients with malignant ascites were randomly divided into D-SOX group (intrape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bin, Yehong, Lan, Dong, Bao, Wenguang, Yang, Haiyan, Zhou, Shengsheng, Huang, Fengxiang, Wang, Man, Peng, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917651/ https://www.ncbi.nlm.nih.gov/pubmed/35279214 http://dx.doi.org/10.1186/s13063-022-06143-w

Ejemplares similares

The expression of Slit2 and Robo1 increased during retinoic acid syndrome in acute promyelocytic leukemia and impacted differentiated cell migration
por: Yang, Haiyan, et al.
Publicado: (2022)

Deoxythymidylate kinase (DTYMK) participates in cell cycle arrest to promote pancreatic adenocarcinoma progression regulated by miR-491-5p through TP53 and is associated with tumor immune infiltration
por: Bao, Wenguang, et al.
Publicado: (2023)

Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites
por: Jiao, Jie, et al.
Publicado: (2020)

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer
por: ZHANG, TING, et al.
Publicado: (2016)

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
por: Kou, Furong, et al.
Publicado: (2021)

Efficacy and safety of ultrasound-guided continuous hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites: a midterm study of 36 patients
por: Wu, Yinbing, et al.
Publicado: (2016)

Is Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites?
por: de Mestier, Louis, et al.
Publicado: (2012)

Treatment of gestational choriocarcinoma and massive ascites by hypothermic intraperitoneal perfusion chemotherapy guided by ultrasound followed by cytoreductive surgery
por: Ba, Ming-Chen, et al.
Publicado: (2013)

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
por: Kondo, Tomohiro, et al.
Publicado: (2016)

Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response
por: Zhang, Yalei, et al.
Publicado: (2022)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma
por: Xiao, Susu, et al.
Publicado: (2022)

Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016)

Evaluation of efficacy and safety for compound kushen injection combined with intraperitoneal chemotherapy for patients with malignant ascites: A systematic review and meta-analysis
por: Yu, Hui-Bo, et al.
Publicado: (2023)

Beware of the ‘Ascites’ Patient: Delayed Presentation of Traumatic Intraperitoneal Bladder Rupture
por: Dat, Anthony, et al.
Publicado: (2015)

The efficacy of traditional chinese medicine combined with hyperthermic intraperitoneal chemotherapy for malignant ascites: A systematic review and meta-analysis
por: Lin, Zhixian, et al.
Publicado: (2022)

Spontaneous intraperitoneal rupture of hepatic hydatid cyst: a rare cause of ascites
por: Limeme, Manel, et al.
Publicado: (2014)

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies
por: Wu, Hai-Tao, et al.
Publicado: (2016)

Reducing Malignant Ascites and Long-Term Survival in a Patient with Recurrent Gastric Cancer Treated with a Combination of Docetaxel and Mistletoe Extract
por: Oh, Sung Jin
Publicado: (2020)

Influence of hyperthermic intraperitoneal chemotherapy on renal blood perfusion
por: Liesenfeld, Lukas F., et al.
Publicado: (2023)

Effect of intraperitoneal and subcutaneous injection of chondroitin sulphate on the growth of solid Ehrlich ascites tumour.
por: Takeuchi, J.
Publicado: (1967)

Isolated Ascites on CT After Blunt Trauma: A Sign of Intraperitoneal Bladder Rupture
por: Zhao, Xiaoni, et al.
Publicado: (2021)

Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites
por: Zhang, Feifei, et al.
Publicado: (2019)

mPEG-PDLLA Micelles Potentiate Docetaxel for Intraperitoneal Chemotherapy in Ovarian Cancer Peritoneal Metastasis
por: Zhang, Yumei, et al.
Publicado: (2022)

Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification
por: Zeng, Wei-Juan, et al.
Publicado: (2015)

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer
por: Wada, Ikuo, et al.
Publicado: (2014)

Management of ascites due to gastrointestinal malignancy
por: Saif, Muhammad W., et al.
Publicado: (2009)

Review of catumaxomab in the treatment of malignant ascites
por: Sebastian, Martin
Publicado: (2010)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Development and validation a simple model for identify malignant ascites
por: Guo, Ying-Yun, et al.
Publicado: (2021)

Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis
por: Fushida, S., et al.
Publicado: (2013)

Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer
por: Zhang, Hong-Wei, et al.
Publicado: (2019)

Managing the toxicities of the FEC-100 followed by docetaxel regimen: The price of success
por: Laing, Kara
Publicado: (2008)

Data to establish the optimal standard regimen and predicting the response to docetaxel therapy
por: Moawad, Emad Y.
Publicado: (2015)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
por: Chang, Yen-Hou, et al.
Publicado: (2016)

Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy
por: Yan, Tristan D, et al.
Publicado: (2006)

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
por: Guchelaar, Niels A. D., et al.
Publicado: (2023)

Short‐term intraperitoneal catheters: An ambulatory care intervention for refractory ascites secondary to cirrhosis during COVID‐19
por: Ngu, Natalie LY, et al.
Publicado: (2021)

Ascites and Serial Plasma Circulating Tumor DNA for Predicting the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis
por: Pu, Xiaolin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2asba85rdu9hsk5g3mau59kald